MSYS jointly publishes bioprocessing data with MIT

RNS Number : 7967R

Microsaic Systems plc

05 March 2019

 

5 March 2019

Microsaic Systems plc

("Microsaic" or the "Company")

Microsaic jointly publishes bioprocessing data with MIT

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, announces its joint publication with Massachusetts Institute of Technology ("MIT") "Using MS for point of need bioprocessing".

Today, Microsaic and MIT will be showcasing the latest results of their collaboration in advancing point of need bioprocessing analysis, at the International Foundation of Process Analytical Chemistry ("IFPAC") 2019, in Washington, DC.

This latest phase in the collaboration looks at the effects of storage and time conditions, feeding strategies, and media type on protein quality, and compares frozen and fresh cell cultures. The new demands of modern bioprocessing (for the manufacture of biologic drugs, or "biologics") together with the implementation of Quality by Design ("QbD") and Process Analytical Technology ("PAT") methods require a deeper understanding of these processes. MS is well placed to provide the information rich data required.

Glenn Tracey, CEO of Microsaic, commented, "Traditional mass spectrometers are large, expensive, and require operation by specialists in centralised laboratories. Integrated real-time MS, decentralized and at the point-of-need, could provide important process information quickly and at a reduced cost. Microsaic is working closely with MIT, at the feasibility of using deployable and compact mass spectrometry for the direct analysis of upstream cell cultures to show a compelling user scenario for our technology."

Biologic drugs represented eight out of ten top selling drugs in 2017, and estimated revenues will reach over $380Bn by 2024. The Directors believe that the total market for bioprocessing equipment in the pharmaceutical industry is currently in the region of $15Bn.

Recently, Microsaic announced its innovative new product, the MiD® ProteinID, which the Analytical Scientist recognised as one of the top innovative products of 2018.

Enquiries:
Microsaic Systems plc Glenn Tracey, CEO Bevan Metcalf, FD	[phone]
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	[phone]
IFC Advisory Ltd (Financial PR) Graham Herring Heather Armstrong Florence Chandler	[phone]

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company works with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines.  MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

The Microsaic's compact MiD® MS systems retain the functionality of larger conventional MS systems, while being easier to use by non-specialists, and consume less energy and have lower running costs. For more information, please go to www.microsaic.com.  

 

END

 

 

NRAFMGGFVDKGLZM